According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The recent approval and launch in chronic obstructive pulmonary disease (COPD ... decision by April 18, 2025, and bullous pemphigoid, for which a supplemental Biologics License Application ...

Instead of being absorbed directly into the bloodstream via smoking, edibles must pass through the digestive system and ...

Axial and coronal unenhanced thin-slice chest HRCT scans (A and B, respectively) in a 25-year-old male cannabis smoker, showing a large (5 cm) bulla (white arrows), sharply demarcated by a thin wall ...

(3) severe cardiac insufficiency (NYHA grade III IV), poor blood pressure control in hypertensive patients or poor blood glucose control in diabetic patients; (4) those with adhesion in the pleural ...

In a phase 1 dose-escalation trial (NCT02573259), 40 patients with advanced solid tumors including melanoma, non–small cell lung cancer, ovarian cancer ... These included fatigue, dermatitis bullous, ...

It is under development for the treatment of prurigo nodularis, grass pollen allergy, gastroenteritis, chronic spontaneous urticaria or hives, dermatitis (eczema), chronic obstructive pulmonary ...

He had a recurrence of pneumothorax secondary to bullous emphysema resulting from his 30-pack-year ... Chest X-ray showed cardiomegaly with emphysematous changes and chronic lung bases atelectasis, ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, ...